Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy

Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy

Abstract Background Breast cancer is the most common malignancy among females. The Tamoxifen and Exemestane Trial (TEXT) and the Suppression of Ovarian Function Trial (SOFT) were two landmark studies, which showed adjuvant therapy with the aromatase inhibitor (AI), exemestane, or tamoxifen combined...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruchi Patel, Elizabeth Weil, Sara Bugamelli, Emma Carroll, Kylie Steinke, Erinn Stockhausen, John Burfeind, Colin Mooney, Janet Retseck, Deepika Sriram, Jutta Deininger, Angela Halbach, Maressa Sweeney, Sailaja Kamaraju, Lubna N. Chaudhary, Yee Chung Cheng
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Breast Cancer Research
Online Access:https://doi.org/10.1186/s13058-025-01979-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-01979-x

Similar Items